poisar

Stock

Spruce Biosciences, Inc. SPRB

$61.88+0.63%

Overview

SPRB market data

Price History

SPRB price chart · 1M
O
62.51
H
62.51
L
61.64
C
61.88
Vol
2,705.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$62.51
Previous Close
$61.49
Day High
$62.51
Day Low
$61.64
52 Week High
$63.97
52 Week Low
$40.68
7 Day Return
+15.88%
30 Day Return
+47.95%
90 Day Return
+25.20%
1 Year Return
+10.68%
Daily Notional Volume
$167.4K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$50.80
Diluted earnings per share over the trailing twelve months.
Beta
3.37
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-1,079.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$7.00 – $240.00
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $137M · P/B 2.19 · P/S 27.89.

Company News

10 captured
Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type BBenzinga · Aug 26, 2026, 12:07 PM
Spruce Biosciences Says It Completed Two Pre-BLA Meetings With FDA Supporting Q4 2026 BLA Submission For Tralesinidase Alfa In Sanfilippo Syndrome Type B; FDA Found CMC Comparability Strategies ReasonableBenzinga · Aug 24, 2026, 1:28 PM
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104Benzinga · Aug 17, 2026, 1:22 PM
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144Benzinga · Aug 13, 2026, 1:58 PM
8-K filing — SPRUCE BIOSCIENCES, INC. (SPRB)SEC EDGAR · Aug 12, 2026, 1:05 PM
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q2 EPS $(6.68) Misses $(5.80) EstimateBenzinga · Aug 12, 2026, 1:03 PM
Spruce Biosciences Announces $5.5M Combined Strategic Investment From Cure Sanfilippo Foundation And National MPS Society To Partially Fund TA-ERT Expanded Access Program In MPS IIIBBenzinga · Aug 12, 2026, 12:04 PM
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160Benzinga · Jul 13, 2026, 1:07 PM
Spruce Biosciences Joins Russell 3000 Index, Effective June 29Benzinga · Jun 29, 2026, 12:10 PM
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123Benzinga · Jun 16, 2026, 12:40 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock
Spruce Biosciences, Inc. (SPRB) stock — price, valuation & news | Poisar